This is the institutional repository for peer reviewed articles published in open access and doctoral dissertations by the Agricultural University of Iceland, the Iceland Academy of the Arts, the National and University Library of Iceland, Reykjavik University, the University of Akureyri, Bifröst University, Hólar University College and the University of Iceland. Open access to research results is in accordance with article 10 from the Act on public support for research / 2003 No 3 and is compliant with requirements from international and domestic research fund programs. The purpose of the Open Science repository is to make results of research conducted at Icelandic universities accessible to the public online without hindrance or charge. Deposits to the repository are permanent and are intended to ensure future access to all published scientific material of the Icelandic research community. By collecting this material together in one collection access is made simple and easy for anyone who wishes to study the considerable scientific work conducted in Iceland.

The repository is OpenAIRE / OpenAIREplus compliant and in accordance with requirements for publication of research results from projects supported by the European research programs FP7 and H2020.

The repository uses the open software DSpace.

Communities in Opin vísindi

Recently Added

  • Icon
    Drug Tolerant Anti-drug Antibody Assay for Infliximab Treatment in Clinical Practice Identifies Positive Cases Earlier 
    Kharlamova, Nastya; Hermanrud, Christina; Dunn, Nicky; Ryner, Malin; Hambardzumyan, Karen; Vivar Pomiano, Nancy; Marits, Per; Gjertsson, Inger; Saevarsdottir, Saedis; Pullerits, Rille; Fogdell-Hahn, Anna (Frontiers Media SA, 2020-07-21)
    A subgroup of patients treated with infliximab lose response to the treatment and one reason for this is the development of anti-drug antibodies (ADA). If used optimally, measuring drug and ADA level could lead to a more personalized and efficient ...
  • Icon
    Samfélag fjölbreytileikans: Samskipti heimamanna og innflytjenda á Íslandi 
    Meckl, Markus; Gunnþórsdóttir, Hermína; Aradóttir, Lilja Rós; Viðarsdóttir, Karitas Nína; Sölvason, Ómar Hjalti; Murdock, Elke; Skaptadóttir, Unnur Dís; Wojtyńska, Anna; Wendt, Margrét; Guðmundsson, Birgir; Eyþórsson, Grétar Þór; Bjarnason, Thoroddur; Barillé, Stéphanie; Hoffmann, Lara; Ragnarsdottir, Hanna (Háskólinn á Akureyri, 2020-12)
  • Icon
    International severe asthma registry (ISAR): protocol for a global registry 
    FitzGerald, J. Mark; Tran, Trung N.; Alacqua, Marianna; Altraja, Alan; Backer, Vibeke; Bjermer, Leif; Björnsdóttir, Unnur; Bourdin, Arnaud; Brusselle, Guy; Bulathsinhala, Lakmini; Busby, John; Canonica, Giorgio W.; Carter, Victoria; Chaudhry, Isha; Cho, You Sook; Christoff, George; Cosio, Borja G.; Costello, Richard W.; Eleangovan, Neva; Gibson, Peter G.; Heaney, Liam G.; Heffler, Enrico; Hew, Mark; Hosseini, Naeimeh; Iwanaga, Takashi; Jackson, David J.; Jones, Rupert; Koh, Mariko S.; Le, Thao; Lehtimäki, Lauri; Lúðvíksdóttir, Dóra; Maitland-van der Zee, Anke H.; Menzies-Gow, Andrew; Murray, Ruth B.; Papadopoulos, Nikolaos G.; Perez-de-Llano, Luis; Peters, Matthew; Pfeffer, Paul E.; Popov, Todor A.; Porsbjerg, Celeste M.; Price, Chris A.; Rhee, Chin K.; Sadatsafavi, Mohsen; Tohda, Yuji; Wang, Eileen; Wechsler, Michael E.; Zangrilli, James; Price, David B. (Springer Science and Business Media LLC, 2020-08-14)
    Background: Severe asthma exerts a disproportionately heavy burden on patients and health care. Due to the heterogeneity of the severe asthma population, many patients need to be evaluated to understand the clinical features and outcomes of severe ...
  • Icon
    Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration 
    Michelsen, Brigitte; Lindström, Ulf; Codreanu, Catalin; Ciurea, Adrian; Zavada, Jakub; Loft, Anne Gitte; Pombo-Suarez, Manuel; Onen, Fatos; Kvien, Tore K; Rotar, Ziga; Santos, Maria Jose; Iannone, Florenzo; Hokkanen, Anna-Mari; Gudbjornsson, Bjorn; Askling, Johan; Ionescu, Ruxandra; Nissen, Michael J; Pavelka, Karel; Sanchez-Piedra, Carlos; Akar, Servet; Sexton, Joseph; Tomsic, Matija; Santos, Helena; Sebastiani, Marco; Österlund, Jenny; Geirsson, Arni Jon; Macfarlane, Gary; van der Horst-Bruinsma, Irene; Georgiadis, Stylianos; Brahe, Cecilie Heegaard; Ørnbjerg, Lykke Midtbøll; Hetland, Merete Lund; Østergaard, Mikkel (BMJ, 2020-09-01)
    OBJECTIVES: To explore 6-month and 12-month secukinumab effectiveness in patients with axial spondyloarthritis (axSpA) overall, as well as across (1) number of previous biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), (2) ...
  • Icon
    Melflufen, a peptide‐conjugated alkylator, is an efficient anti‐neo‐plastic drug in breast cancer cell lines 
    Schepsky, Alexander; Traustadóttir, Gunnhildur Ásta; Jóelsson, Jón Pétur; Ingþórsson, Sævar; Kricker, Jennifer; Bergthorsson, Jon Thor; Ásbjarnarson, Árni; Gudjonsson, Thorkell; Nupponen, Nina; Slipicevic, Ana; Lehmann, Fredrik; Gudjonsson, Thorarinn (Wiley, 2020-07-27)
    Melphalan flufenamide (hereinafter referred to as “melflufen”) is a peptide-conjugated drug currently in phase 3 trials for the treatment of relapsed or refractory multiple myeloma. Due to its lipophilic nature, it readily enters cells, where it is ...

View more